Recrutamento encerrado
FASE
Número Europeu 2017-003344-21
7465-CL-0301
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Detalhes
Destaques